基于生物发光共振能量转移 （BRET） 的测定法，用于测量 CRAF 与活细胞中 14-3-3 蛋白的相互作用
March 1st, 2024
2K views
该方案描述了一种基于 BRET 的测定法，用于测量 CRAF 激酶与活细胞中 14-3-3 蛋白的相互作用。该协议概述了准备细胞、读取 BRET 发射和数据分析的步骤。还提供了一个示例结果，其中确定了适当的对照和分析优化的故障排除。
我们研究的主要重点是通过研究罕见病相关突变来发现 Ras-MAPK 激酶通路中的新脆弱性。我们最近开发了另一种基于 BRET 的测定法，用于测量活细胞中 RAF 激酶的自身抑制活性。重要的是，该测定对于表征 BRAF 富含半胱氨酸结构域中的一组罕见种系突变至关重要，这证明了该结构域对于维持 BRAF 自身抑制和防止组成型 BRAF 生物活性至关重要。
该测定法测量 1433 种蛋白质与 RAF 激酶 CRAF 的相互作用，这些相互作用在介导发育和疾病中的 RAF 功能中起着重要作用。此外，该测定与先前建立的用于测量 RAF 自身抑制和 RAF-RAF 相互作用的测定相结合，构成了剖析活细胞中 RAF 激酶调节机制的工具包的基础。
概述
本协议描述了一种基于BRET的检测方法，用于测量活细胞中CRAF激酶与14-3-3蛋白的相互作用。该检测方法对于理解RAF激酶在发育和疾病中的调控机制至关重要。
关键研究组成部分
科学领域
- 细胞生物学
- 生物化学
- 信号转导
背景
- RAS-MAP激酶途径对于各种细胞过程至关重要。
- RAF激酶，包括B-RAF和C-RAF，是该途径中的关键调节因子。
- 14-3-3蛋白与RAF激酶相互作用，影响其功能。
- 理解这些相互作用可以揭示罕见疾病突变的见解。
研究目的
- 测量CRAF与14-3-3蛋白的相互作用。
- 表征RAF激酶中特定突变的作用。
- 开发用于研究活细胞中RAF调控的工具包。
使用的方法
- 为BRET检测准备293 FT细胞。
- 测量BRET发射以评估蛋白质相互作用。
- 数据分析用于检测优化和控制识别。
- 使用先前建立的检测进行全面分析。
主要结果
- 成功测量CRAF和14-3-3蛋白相互作用。
- 识别RAF激酶中自动抑制的关键域。
- 展示该检测方法在研究罕见突变中的实用性。
- 建立了未来RAF相关研究的框架。
结论
- 基于BRET的检测方法对于研究RAF激酶相互作用是有效的。
- 获得的见解可以为相关疾病的治疗策略提供信息。
- 这项工作有助于理解RAF激酶的调控。
常见问题
什么是基于BRET的检测？
基于BRET的检测测量两种蛋白之间的生物发光共振能量转移，指示它们在活细胞中的相互作用。
为什么14-3-3蛋白很重要？
14-3-3蛋白调节各种信号通路，对RAF激酶的正常功能至关重要。
这个检测方法如何帮助疾病研究？
通过理解RAF激酶相互作用，研究人员可以识别与RAS-MAP途径失调相关疾病的潜在治疗靶点。
本协议中使用了什么细胞系？
本协议使用293 FT细胞进行BRET检测。
协议的关键步骤是什么？
关键步骤包括细胞准备、BRET发射测量和用于优化的数据分析。
RAF自动抑制的意义是什么？
RAF自动抑制对于防止不受控制的细胞信号传导至关重要，这可能导致癌症和其他疾病。
Executive Industry Relevance
Quantitative measurement of CRAF and 14-3-3 protein interactions in live cells addresses a critical challenge in target validation for RAS-MAPK pathway drug discovery. This BRET-based assay enables mechanistic de-risking by directly interrogating regulatory protein-protein interactions implicated in oncogenic signaling and rare disease. The approach supports predictive confidence at the early discovery and target triage inflection point for portfolio advancement.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct interrogation of CRAF-14-3-3 interactions central to RAS pathway regulation.
- Supports functional validation of disease-relevant mutations affecting RAF kinase activity.
- Facilitates mechanistic de-risking by quantifying effects of specific mutations on protein binding.
- Provides a live-cell context for assessing regulatory protein interactions relevant to disease biology.
Screening & Assay Development
- Delivers a validated, quantitative assay platform for measuring protein-protein interactions in live cells.
- Enables reproducible detection of interaction disruption by site-specific mutations.
- Supports assay standardization and scalability for compound screening targeting RAF-14-3-3 interfaces.
- Generates robust quantitative outputs suitable for downstream screening workflows.
Translational & Preclinical Research
- Aligns with disease-relevant systems by modeling interactions implicated in cancer and RASopathies.
- Provides continuity from mechanistic discovery to preclinical validation of pathway modulation.
- Enables risk-adjusted advancement decisions based on quantitative interaction data.
Pipeline & Workflow Integration
This BRET-based assay integrates into the discovery continuum from early target validation through lead identification and preclinical research, supporting both mechanistic studies and screening campaigns.
- Discovery Biology: Quantifies regulatory protein interactions to clarify pathway mechanisms and validate therapeutic hypotheses.
- Screening: Provides assay readiness and reproducibility for evaluating modulators of CRAF-14-3-3 binding.
- Analytics: Delivers quantitative BRET ratios and mutation-dependent readouts for comparative analysis.
- Translational Research: Models disease-relevant protein interactions for preclinical continuity.
- Enterprise Reuse: Establishes a reusable toolkit for dissecting RAF kinase regulation in live-cell systems.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Standardizes live-cell interaction assays for reproducibility and scalability.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency by de-risking early targets.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of RAS pathway programs.
Implementation Considerations
- Requires expertise in live-cell assay development and protein interaction analysis.
- Needs access to multi-mode plate readers and quantitative BRET detection infrastructure.
- Demands cross-team standardization for assay setup, data analysis, and protein expression validation.
- Adaptation may be needed for different cell lines or RAF isoforms based on research focus.
- Assay sensitivity and specificity depend on construct design and mutation selection as demonstrated in the protocol.
Biopharma FAQs
Why does null hypothesis testing matter for CRAF-14-3-3 BRET assays?
Null hypothesis testing enables objective determination of whether observed BRET signals reflect true CRAF-14-3-3 interactions or background, supporting rigorous target validation and reducing false positives in early discovery.
How does independent variable isolation fit the CRAF-14-3-3 interaction workflow?
By introducing specific mutations at RAF docking sites, the assay isolates the effect of each variable on the BRET signal, clarifying the mechanistic contribution of individual residues to protein binding.
What do quantitative BRET ratio measurements enable in this assay?
Quantitative BRET ratios provide a direct, scalable readout of interaction strength, enabling comparison across mutants and conditions to inform mechanistic de-risking and screening decisions.
Why are replication requirements critical for cross-functional CRAF-14-3-3 studies?
Replication ensures that observed interaction changes are robust and reproducible, facilitating reliable data sharing and decision-making across discovery, screening, and translational teams.
What statistical analysis capabilities are required before BRET assay implementation?
Teams must be able to calculate corrected BRET ratios, assess significance of interaction changes, and interpret quantitative outputs to support confident advancement of validated targets.
